stella

Lupus

June 2026 Research Brief

Read our full Lupus guide →

Active sponsors

Trials

Drug / interventionPh 1
HBM7020 drug safety and absorption in healthy adults and those with B-cell autoimmune diseases like lupus.

A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body

Otsuka Pharmaceutical Development & Commercialization, Inc.Posted: Jun 2026NCT07649265
ObservationalPh 1
ABBV-519 drug safety and effectiveness via infusion or injection in adults with lupus or rheumatoid arthritis.

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

AbbViePosted: May 2026NCT07607964
BiologicPh 4
LUPKYNIS combined with three different drugs to treat kidney inflammation from lupus.

PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

Aurinia Pharmaceuticals Inc.Posted: May 2026NCT07611214
Aurinia Clinical Trials Informationclinicaltrials@auriniapharma.com
Vaccine
Shingrix vaccine response comparison between lupus patients and matched healthy controls.

Reduced Vaccine Response to HZ/su in SLE

Seoul National University HospitalPosted: Jun 2026NCT07636044
Jin Kyun Park, MDjinkyunpark@snu.ac.kr
Lupus nephritisPh 1
Cevostamab drug safety and effects in lupus patients with or without kidney involvement.

To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Genentech, Inc.Posted: Jun 2026NCT07629583
Cell therapyPh 1 (early)
Arnovie101 mRNA therapy safety for B-cell autoimmune diseases including lupus and autoimmune hemolytic anemia.

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)

Circunited BioPharma (Shenzhen) Co., Ltd.Posted: Jun 2026NCT07629596
Yajing Zhang, M.D.yajing_cart66@126.com
BiologicPh 2
Anifrolumab injection safety and effects in children ages 5-18 with moderate to severe lupus.

A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

AstraZenecaPosted: Jun 2026NCT07630714
AstraZeneca Clinical Study Information Centerinformation.center@astrazeneca.com
Exercise intervention
Aerobic exercise effects on disease activity and thinking skills in lupus patients over 12 weeks.

The Effect of Exercise on Cognitive Functions in Individuals With Systemic Lupus Erythematosus

Istanbul Galata UniversityPosted: Jun 2026NCT07622251
Cell therapyPh 1 (early)
IASO207 CAR-T cell therapy safety and effectiveness for treatment-resistant lupus.

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

Peking University People's HospitalPosted: Jun 2026NCT07617740
Xiangyu Zhao, M.D,Ph.Dzhao_xy@bjmu.edu.cn
DiagnosticsPh 4
Ultrasound screening strategy to prevent heart attacks in patients with inflammatory rheumatic diseases.

Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)

Instituto de Investigación Marqués de ValdecillaPosted: May 2026NCT07611747

Showing trials with activity in the past 30 days. See the full Lupus research landscape →

Condition guide

Lupus — the full picture

Research landscape, trial types, and what eligibility typically looks like — written for patients but useful for everyone.

Read the condition guide →

Monthly digest

Get this brief every month

We’ll email you the Lupusbrief as soon as it’s published — no login required.

Coming soon